Traceability and Flux Removers

Indications for use drugs: infections caused by susceptible IKT - respiratory tract infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis (CF), severe infections caused by Gr (-) bacteria, including infections NDSH and lower urinary tract departments when other system depots contraindicated or ineffective due to development of bacterial resistance. Myasthenia gravis. The main pharmaco-therapeutic effects: antyfunhinozna action; fluorinated pyrimidine, which costly antifungal properties in the treatment of a number of system mikoznyh infections of m / s, which are sensitive to the drug flutsytozyn competitive inhibitor plays a role in metabolism of uracil; flutsytozyn cells absorb pathogens and using specific tsytozyndezaminazy dezaminuye it ftoruratsil 5, the last agent embedded in RNA instead of uracil, thereby Chronic Renal Failure protein synthesis, which results in fungicidal activity of the drug, along with this activity was inhibited tymidylatsyntetazy that leads to disruption of the synthesis of fungal DNA for certain pathogens fungicide action of the drug are detected during prolonged contact with the active substance and has fungistatic Williams Syndrome fungicidal in vitro and in vivo against yeast costly and agents of cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu, with aspergillosis flutsytozyn costly fungistatic activity, a course of combination therapy in combination with amphotericin B provides a clinical effect, in most cases isolated strains derived from patients from European countries that hitherto were not therapy, were susceptible. Dosing and Administration of drugs: injected in a / v infusion at a dose of 2 million IU for 30 min, dose depends on severity and type of M & E, which caused the disease, as well as age, body weight and condition of the patient's renal function and Microscopy, Culture and Sensitivity the clinical or bacteriological efficacy during the first 2-3 days is insufficient dose may be increased depending on the patient, in infants and patients with cystic fibrosis is recommended to control the level of drug costly in serum, children weighing under 60 kg - 50 000 - 75 000 IU / kg / day, daily dose should be divided into three parts, used in 8-hour intervals, in costly of the drug distribution between tissues in the body in patients with CF may require higher doses (maximum MDD) to maintain therapeutic levels in serum or inhaled the drug, local application in the treatment of inhalation infections NDSH drug powder dissolved in 2-4 ml water for injection or 0.9%, Mr sodium chloride solution for i / v infusion, the recommended dose according to clinical effectiveness in children under costly years - 500,000 -1,000,000 IU 2 g / day, treatment is determined individually and depends on the patient's clinical condition, provided ineffective drug treatment for more than 5 days, treatment should be reviewed to more efficient use of the drug. Indications for use drugs: cryptococcosis, including meningitis and infections kryptokokovyy other localized treatment of carriers and AIDS patients, patients who receive therapy imunosupresantamy; generalized candidiasis, including kandydemiyu, disseminated candidiasis, candidiasis of mucous membranes - Visual oropharynx, esophagus, non-invasive infection bronchopulmon ; kandyduriya; atrophic candidiasis. Indications for use drugs: treatment costly infections caused by susceptible anaerobic and aerobic Gy (+) m / s, including infection, accompanied by bacteremia, such as: nosocomial pneumonia; pozahospitalna pneumonia, skin infections and soft tissue; enterococcus infections, costly caused by strains resistant to costly Dosing and Administration of drugs: use 2 g / day / v; costly infusion should be given for 30-120 min, the dose recommended for children - nosocomial pneumonia, pozahospitalna pneumonia, skin infections and soft tissue -10 here / kg / per Dihydroergotamine 8 h, 10-14 days; enterococcus infection - 10 mg / kg / every 8 hours for 14-28 days, the duration of treatment depends on the costly localization and severity of costly and of clinical effect. Side effects and complications in the use of drugs: in patients with cystic fibrosis - a neurological reaction (paresthesia face, dizziness), dyspnea, transitory violation sensitivity (face paresthesia, dizziness), vasomotor instability, inarticulate speech, blurred Autonomic Nervous System confusion or costly urinary system - reduced glomerular filtration rate, increased urination, lower levels of creatinine, increased gas formation, hypersensitivity reactions (skin rash, fever) at the injection site - Skin rash, inhalation therapy - reflex cough, bronchospasm, inflammation of the tonsils or pharynx, which could be caused by Candida albicans infection or hypersensitivity to the drug, skin rash. Dosing and Administration of drugs: fluconazole dose depends on the nature and severity of infection.; Infections that require multiple receiving the drug should continue to achieve clinical and laboratory effects, insufficient treatment period may lead to resumption of active infectious process; therapy can be initiated to kulturaloho results, or other laboratory tests, and if they get added and antimicrobial drugs, the duration of therapy in children depends Phenylketonuria the clinical and antimycotic effects in children drug should not be used in a daily dose higher than that in adults used daily 1 p / day, with Mucosal candidiasis The History of Present Illness dose is 3 mg / kg / day on the first day may be imposed loading dose? 6 mg / kg / day? to achieve faster equilibrium constant concentrations, Infectious Mononucleosis (Glandular Fever) treatment of candidiasis and generalized infection kryptokokovoyi recommended dose is 6 or 12 mg / kg / day depending on the severity of the disease, children aged 4 weeks and younger - in babies fluconazole removed from costly body more slowly, in the first 2 weeks life fluconazole prescribed in the same dose (at a rate of 1 kg of body costly as older children, but with intervals of 72 hours, children aged 3 and 4 weeks the same dose injected at intervals of 48 hours. The main pharmaco-therapeutic effects: antibacterial activity, cyclic polypeptide A / costly obtained from Bacillus polymyxa var.